Investment Banking
Joint Sales Agent on Viking Therapeutics’ $500.0 Million ATM Offering
August 12, 2026
Oppenheimer & Co. Inc. acted as Joint Sales Agent on Viking Therapeutics’ $500.0 Million ATM Offering
Viking Therapeutics, Inc. has entered into a Sales Agreement relating to the sale of shares of their common stock. In accordance with the terms of the Sales Agreement, Viking may offer and sell shares of common stock from time to time through or to the Agents, with an aggregate offering of up to $500,000,000.
Do Not Solicit Purchases.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Name:
Nicholas Beyar
Title:Executive Director, Healthcare Life Sciences Investment Banking
Name:
Matthew Karpf
Title:Executive Director, Healthcare Life Sciences Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 9071352.1